Contracts › 75N98026P00871
75N98026P00871: Nulisa (A Novel Proteomic Liquid Biopsy Platform With Attomolar Sensitivity and High Multiplexing) Testing Services to Identify Biomarkers That Provide Information About the Underlying Molecular Changes Associated With Ad/Adrd.
Awarded to Banner Health by National Institutes of Health (NIH).
$2.3Mobligated
$7.0Mpotential value
31 July 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N98026P00871 |
|---|---|
| Awardee | Banner Health |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH OLAO |
| NAICS | 541380 Testing Laboratories and Services |
| PSC | Q301 Reference Laboratory Testing |
| Place of performance | MD |
| Offers received | 2 |
| Period of performance | 01 August 2026 to 31 July 2027 |
| Potential end | 31 July 2029 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541380 contracts · All expiring contracts · USASpending record